Core Insights - ABVC BioPharma, Inc. announced the acquisition of TT Life Company by its subsidiary AiBtl BioPharma Inc. for approximately $8.33 million, involving a share swap of 1.66 million shares at $5 per share [1][2] - The acquisition aims to enhance AiBtl's capabilities in precision medicine, combining its global development expertise with TT Life's design and manufacturing strengths [2][3] - TT Life Company is projected to achieve targeted sales of $10 million in 2024, with a net profit margin of 11% [5] Company Overview - ABVC BioPharma is a clinical-stage biopharmaceutical company with a pipeline of six drugs and one medical device under development, utilizing in-licensed medicine from renowned research institutions [6] - AiBtl BioPharma focuses on integrating health and resort industries, aiming to deliver AI-powered products and services [4] - TT Life Company specializes in precision medicine, known for its innovative cell-related products and strong marketing presence in Asia, particularly Malaysia [5]

Core Insights - ABVC BioPharma, Inc. has entered a licensing agreement with OncoX to advance treatments for Non-Small Cell Lung Cancer (NSCLC) through the development of a botanical drug extract from Maitake Mushroom [1][2][3] Company Overview - ABVC BioPharma is a clinical-stage biopharmaceutical company focused on developing therapeutic solutions in ophthalmology, CNS, and Oncology/Hematology [1][6] - The company has an active pipeline of six drugs and one medical device, utilizing in-licensed technology from renowned research institutions [6] Licensing Agreement Details - The agreement grants OncoX exclusive rights to develop, manufacture, and commercialize BLEX 404, a combination therapy drug for NSCLC [2][4] - ABVC and its affiliate will receive an aggregate license fee of $12.5 million, with an additional milestone payment of $1.25 million after OncoX's next fundraising round [1][4] - Royalties of 5% on net sales of BLEX 404, capped at $12.5 million, will also be provided after the product launch [1][4] Market Potential - The global cancer therapeutics market is projected to grow from $164 billion in 2022 to approximately $393.61 billion by 2032, at a CAGR of 9.20% [5] - The lung cancer market was valued at $29.5 billion in 2022 and is expected to grow at an 11% CAGR through 2032 [5] Clinical Development - The FDA has approved four INDs for ABVC's products, including ABV-1519 for NSCLC, which is proposed as a combination therapy with chemotherapy [2][4] - BLEX 404, containing β-glucan from Maitake mushrooms, has shown promising results in clinical studies and is expected to improve treatment outcomes for NSCLC patients [2][4][3]

Core Viewpoint - ABVC BioPharma, Inc. has entered into a term sheet with OncoX BioPharma, Inc. for a licensing agreement concerning its Oncology/Hematology pipeline, which is expected to significantly enhance the company's market position and financial outlook [1][2]. Group 1: Licensing Agreement Details - The licensing agreement will cover clinical trial, registration, manufacturing, supply, and distribution rights for the Licensed Products [1]. - ABVC is set to receive $50 million in licensing fees and an additional $5 million milestone payment after the first fundraising round, along with 5% royalties on net sales, capped at $50 million [1]. - OncoX will have exclusive global rights to develop and commercialize the Licensed Products and will be responsible for regulatory filings and commercialization efforts [3][4]. Group 2: Product Pipeline and Market Potential - ABVC's product pipeline includes six drugs and one medical device, with ongoing clinical development supported by partnerships with renowned research institutions [6]. - The global cancer therapeutics market is projected to grow from $164 billion in 2022 to approximately $393.61 billion by 2032, reflecting a CAGR of 9.20% from 2023 to 2032 [5].

As filed with the Securities and Exchange Commission on March 22, 2024 Registration No. 333-276500 Registration No. 333-271416 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 3 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ABVC BIOPHARMA, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Nevada 5084 26-0014658 (I.R.S. Employer Identification Number) 44370 Old Wa ...

Core Insights - ABVC BioPharma, Inc. announced that its subsidiary AiBtl BioPharma Inc. has entered into an agreement to exchange a 100% ownership stake in certain real estate for 1,533,333 shares of AIBL stock at $5 per share, with the property valued at approximately $7.6 million [1][2] Group 1: Company Developments - The agreement is expected to add several hundred million dollars in value to ABVC's assets, which currently have a market cap of $12 million, indicating that the company is significantly undervalued [2] - The real estate will be utilized to establish controlled-condition farms for growing botanicals, which will help reduce manufacturing costs for ABVC's drug products and facilitate clinical studies at a lower expense [2][3] - A portion of the real estate will also be developed into a senior citizen rehabilitation center, contributing to cost savings and revenue generation for AIBL's major shareholder, ABVC [2] Group 2: Company Overview - ABVC BioPharma is a clinical-stage biopharmaceutical company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus®) under development [3] - The company collaborates with renowned research institutions, including Stanford University and Cedars-Sinai Medical Center, to conduct proof-of-concept trials through Phase II of clinical development [3] - For its medical device, Vitargus®, ABVC intends to conduct global clinical trials through Phase III [3]

Core Insights - ABVC BioPharma, Inc. reported its 2023 annual financial and operating results, highlighting a significant decrease in revenue and a reduction in net loss compared to the previous year [1][13][14]. Financial Performance - Revenues for 2023 were $152,430, down approximately 84% from $969,783 in 2022, primarily due to the completion of ongoing projects and awaiting new approvals [13]. - Operating expenses decreased to $8,066,902 in 2023 from $15,797,780 in 2022, mainly due to reduced stock-based compensation and lower selling, general, and administrative expenses [13]. - The net loss for 2023 was $10,910,288, a reduction of approximately 31% from the net loss of $16,312,374 in 2022, attributed to more effective funding usage and discontinuation of certain consulting services [14]. Licensing and Strategic Agreements - The company entered a multi-year global licensing agreement with AiBtl BioPharma Inc. for CNS drugs targeting Major Depressive Disorder (MDD) and Attention Deficit Hyperactivity Disorder (ADHD), receiving 23 million shares of AIBL stock valued at $10 per share [3][21]. - ABVC also signed a cooperation agreement with Zhong Hui Lian He Ji Tuan, Ltd., acquiring 20% ownership of a property in Leshan, Sichuan, China, valued at $37 million, to develop a healthcare center [5][10]. Compliance and Equity - The company regained compliance with Nasdaq Marketplace Rules regarding minimum bid price and stockholders' equity requirements [4]. - As of December 31, 2023, total stockholders' equity was reported at $8,388,050, an increase from $3,098,585 in 2022 [13][31]. Research and Development Highlights - ABVC received multiple patents for Polygala extract for treating MDD and ADHD, with patents valid until 2040 and 2041 [16]. - The company successfully completed Phase II trials for MDD and commenced Phase IIb trials for ADHD, with further studies planned for 2024 [18]. Cash Flow and Investments - Cash and cash equivalents as of December 31, 2023, were $60,155, down from $85,265 in 2022 [15]. - The company reported net cash used in operating activities of $4,235,845 for 2023, an improvement from $7,398,391 in 2022 [36].

[Executive Summary & Corporate Updates](index=1&type=section&id=Executive%20Summary%20%26%20Corporate%20Updates) ABVC BioPharma announced 2023 financial results and Q1 2024 updates, regained Nasdaq compliance, and pursued strategic licensing and real estate investments [Introduction](index=1&type=section&id=Introduction) ABVC BioPharma, Inc. announced its 2023 annual financial and operating results, along with a fiscal year 2024 first-quarter business update, as detailed in its Form 10-K filing - ABVC BioPharma, Inc. (NASDAQ: ABVC) is a biotechnology company focused on botanically based solutions[1](index=1&type=chunk) - The company announced its 2023 annual financial and operating results and a fiscal year 2024 first-quarter business update[1](index=1&type=chunk) [Nasdaq Compliance](index=1&type=section&id=Nasdaq%20Compliance) ABVC BioPharma successfully regained compliance with Nasdaq Marketplace Rules by meeting the minimum $1.00 bid price and $2.5 million minimum stockholders' equity requirements in August and September 2023, respectively - Regained compliance with Nasdaq's **minimum $1.00 bid price requirement** by August 8, 2023[4](index=4&type=chunk) - Regained compliance with Nasdaq's **$2.5 million minimum stockholders' equity requirement** by September 6, 2023[4](index=4&type=chunk) [Strategic Business Developments](index=1&type=section&id=Strategic%20Investments) The company engaged in significant strategic initiatives, including a global licensing agreement for CNS drugs and substantial real estate investments aimed at developing healthcare centers and plant factories, with plans to generate new revenue streams from these assets [Licensing Agreements](index=1&type=section&id=Licensing%20Deal) ABVC and its subsidiary BioLite entered a multi-year global licensing agreement with AiBtl BioPharma Inc. (AIBL) for CNS drugs (MDD and ADHD), receiving 23 million shares of AIBL stock each, with potential future milestones and royalties - Entered a multi-year, global licensing agreement with AiBtl BioPharma Inc. (AIBL) for CNS drugs (MDD and ADHD)[3](index=3&type=chunk) - ABVC and BioLite each received **23 million shares of AIBL stock**, valued at **$10 per share**, giving ABVC a controlling interest in AIBL[3](index=3&type=chunk) - Eligible to receive **$3.5 million** and **5% royalties on net sales** (up to $100 million) if certain milestones are met[3](index=3&type=chunk) [Real Estate Investments & Revenue Generation](index=1&type=section&id=Strategic%20Investments_RealEstate) ABVC made strategic real estate acquisitions in China and elsewhere, intending to develop healthcare centers and plant factories for its botanical pipeline. The company has begun leveraging these assets by licensing healthcare expertise and leasing properties to generate revenue - Acquired **20% ownership of a property in Leshan, Sichuan, China**, valued at **$37 million**, for joint development into a healthcare center[5](index=5&type=chunk) - Acquired an additional real estate asset in February 2024 to develop plant factories for its botanical pipeline, with the property valued at approximately **$2,962,232**[6](index=6&type=chunk) - Executed an agreement to license healthcare-related expertise ('Know-How') to Senior Paradise, Inc. (SPI) for **$3 million** (cash or stock) and **2% royalties** on SPI's revenues from projects on leased land, marking the first revenue generation from real estate acquisitions[7](index=7&type=chunk) [Capital Structure & Stockholders' Equity](index=2&type=section&id=Stockholders%27%20Equity) The company engaged in several financing activities, including issuing convertible notes to Lind Global Fund II, LP and conducting a registered direct offering, which contributed to a significant increase in total stockholders' equity to $8,388,050 by December 31, 2023 - Issued a secured, convertible note to Lind Global Fund II, LP in February 2023 for **$3,175,000**, with a principal amount of **$3,704,167**[8](index=8&type=chunk) - Completed a registered direct offering in July 2023, selling **300,000 common shares** and **200,000 pre-funded warrants** for gross proceeds of **$1,750,000**[9](index=9&type=chunk) - Issued additional secured, convertible notes to Lind in November 2023 (**$1,000,000 purchase price**) and January 2024 (**$833,333 purchase price**), both with warrants[12](index=12&type=chunk)[13](index=13&type=chunk) Stockholders' Equity | Metric | As of Dec 31, 2023 | | :----- | :----------------- | | Total Stockholders' Equity | $8,388,050 | [Key Financial Highlights (2023 vs 2022)](index=3&type=section&id=Key%20Financial%20Highlights) In 2023, ABVC BioPharma experienced an 84% decrease in revenues due to project completion but significantly reduced its net loss by 31% through decreased operating expenses, particularly in stock-based compensation and R&D, despite an increase in interest expense Revenue Comparison (2023 vs 2022) | Metric | 2023 | 2022 | Change (%) | | :----- | :----------- | :----------- | :--------- | | Revenues | $152,430 | $969,783 | -84% | Operating Expenses Comparison (2023 vs 2022) | Metric | 2023 | 2022 | Change | | :--------------- | :----------- | :------------- | :----- | | Operating Expenses | $8,066,902 | $15,797,780 | Decreased | | Stock-based Comp | (Decreased by $6,100,337) | | | | R&D Expenses | (Decreased by $1,630,541) | | | Net Loss and Cash & Cash Equivalents (2023 vs 2022) | Metric | 2023 | 2022 | Change (%) | | :----- | :------------- | :------------- | :--------- | | Net Loss | $(10,910,288) | $(16,312,374) | -31% | | Cash & Cash Equivalents | $60,155 | $85,265 | -29.5% | [Research & Development (R&D) Updates](index=4&type=section&id=Recent%20R%26D%20Operational%20Highlights) The company advanced its neurology, ophthalmology, and oncology pipelines with new patents, regulatory approvals, and clinical trial progress [Patents & Regulatory Approvals](index=4&type=section&id=Patents%20and%20FDA%20Approvals) ABVC BioPharma secured multiple patents in the US, Taiwan, and Australia for its Polygala extract in treating MDD and ADHD, and for corneal tissue preservation. The company also received several US FDA and Taiwan FDA Investigational New Drug (IND) approvals for its oncology pipeline - Received US, Taiwanese, and Australian patents for Polygala extract for Major Depressive Disorder (MDD) and Attention Deficit Hyperactive Disorder (ADHD)[17](index=17&type=chunk) - Obtained a Taiwanese Patent (TW I792427) for Storage Media for the Preservation of Corneal Tissue[17](index=17&type=chunk) - Received US FDA approval for IND ABV-1519 for EGFR Wild-type Non-Small Cell Lung Cancer (NSCLC) in December 2022, followed by Taiwan FDA approval in January 2024[18](index=18&type=chunk) - Total of **four US FDA approved INDs**: ABV-1501 (Triple Negative Breast Cancer), ABV-1519 (NSCLC), ABV-1702 (Myelodysplastic Syndrome), and ABV-1703 (Pancreatic Cancer Therapy)[18](index=18&type=chunk) [Clinical Pipeline Updates](index=4&type=section&id=Clinical%20Pipeline%20Updates) ABVC BioPharma provided updates across its neurology, ophthalmology, and oncology/hematology pipelines, including successful completion of MDD Phase II trials, ongoing ADHD Phase IIb trials, and progress in its vitreous substitute and cancer therapies, alongside new licensing agreements [Neurology](index=4&type=section&id=Neurology) The MDD Phase II trials for ABV-1504 were successfully completed, with preparations for Phase III underway. ADHD Phase IIb trials are ongoing, with an interim report expected by early Q2 2024, and a Phase I study for MDD in cancer patients is set to begin in Q2 2024. The company also signed a licensing term sheet for MDD and ADHD drugs in China and a global licensing agreement with AIBL - MDD Phase II trials for ABV-1504 completed successfully, with good tolerance and no serious adverse effects, ready for End-of-Phase 2 FDA meeting[19](index=19&type=chunk) - ADHD Phase IIb trials commenced at UCSF and five Taiwan sites, with an interim report expected by **early Q2 2024**[19](index=19&type=chunk) - ABV-1601 for MDD in cancer patients has completed Phase I study preparation and is set to initiate in **Q2 2024**[19](index=19&type=chunk) - Signed a legally binding term sheet with Xinnovation Therapeutics Co., Ltd. for exclusive licensing of ABV-1504 (MDD) and ABV-1505 (ADHD) in mainland China, with a possible aggregate income of **$20 million**[20](index=20&type=chunk) - Entered a global licensing agreement with AIBL for MDD and ADHD CNS drugs, valued at **$667 million** by a third-party evaluation[21](index=21&type=chunk) [Ophthalmology](index=4&type=section&id=Ophthalmology) Vitargus, a biodegradable hydrogel vitreous substitute, completed its feasibility study in Australia and received TGA approval for the next trial phase. ABVC also received approval to establish a pilot GMP facility in Taiwan for Vitargus production, with construction expected to complete in 2025 - Vitargus, a vitreous substitute, completed its feasibility study in Australia and received Australian TGA approval to initiate the next trial phase[22](index=22&type=chunk) - Approved by Taiwan Science Park Administration to set up a pilot Good Manufacturing Practice (GMP) facility for Vitargus production, with construction expected to complete in **2025**[23](index=23&type=chunk) [Oncology/Hematology](index=5&type=section&id=Oncology%2FHematology) The US FDA approved the Investigational New Drug (IND) application for BLEX 404 (active ingredient in ABV-1519) for advanced inoperable or metastatic EGFR wild-type non-small cell lung cancer, marking the fourth IND approval for BLEX 404 - US FDA approved IND application for BLEX 404 (active ingredient in ABV-1519) for advanced inoperable or metastatic EGFR wild-type non-small cell lung cancer[24](index=24&type=chunk) - This is the **fourth IND approved by the US FDA for BLEX 404**, with previous approvals for triple-negative breast cancer, myelodysplastic syndromes (MDS), and pancreatic cancer[24](index=24&type=chunk) [Contract Development and Manufacturing Organization (CDMO) Services](index=5&type=section&id=CDMO) BioKey, a subsidiary, expanded its dietary supplement production and secured new clinical development service contracts [CDMO Overview](index=5&type=section&id=CDMO_Overview) BioKey, a wholly-owned subsidiary, continues to produce maitake mushroom dietary supplements and has entered the second year of a distribution agreement, with plans to produce an additional $1 million worth of products. BioKey also secured two ANDA approvals and a three-year, $3 million contract for clinical development services for clients - BioKey, a wholly-owned subsidiary, produces maitake mushroom dietary supplements and is set to produce an additional **$1 million worth of products** for the global market[25](index=25&type=chunk) - Received **two ANDA approvals** from the US FDA for clients[25](index=25&type=chunk) - Secured a **three-year contract worth up to $3 million** for clinical development services with Rgene Corporation[25](index=25&type=chunk) [Company Profile](index=5&type=section&id=About%20ABVC%20BioPharma) ABVC BioPharma is a clinical-stage biopharmaceutical company with a diverse pipeline, leveraging in-licensed technology for drug and medical device development [Company Profile Overview](index=5&type=section&id=Company%20Profile_Overview) ABVC BioPharma is a clinical-stage biopharmaceutical company with a pipeline of six drugs and one medical device, leveraging in-licensed technology from renowned research institutions for clinical development, with plans for global Phase III trials for its medical device, Vitargus - ABVC BioPharma is a clinical-stage biopharmaceutical company with an active pipeline of **six drugs and one medical device** (ABV-1701/Vitargus)[26](index=26&type=chunk) - Utilizes in-licensed technology from institutions like Stanford University, UCSF, and Cedars-Sinai Medical Center for proof-of-concept trials through Phase II[26](index=26&type=chunk) - Intends to conduct global clinical trials through **Phase III for Vitargus**[26](index=26&type=chunk) [Financial Statements](index=6&type=section&id=Financial%20Statements) The company's 2023 financial performance showed increased assets and stockholders' equity, reduced net loss, but decreased revenues compared to 2022 [Consolidated Balance Sheets](index=6&type=section&id=CONSOLIDATED%20BALANCE%20SHEETS) As of December 31, 2023, total assets increased to $14.49 million from $9.58 million in 2022, driven primarily by a significant increase in property and equipment. Total liabilities remained relatively stable at $6.36 million, while total stockholders' equity more than doubled to $8.39 million Consolidated Balance Sheet Highlights | Metric | Dec 31, 2023 | Dec 31, 2022 | Change | | :-------------------------- | :----------- | :----------- | :----- | | Total Assets | $14,492,599 | $9,579,574 | +51.3% | | Property and equipment, net | $7,969,278 | $573,978 | +1287% | | Total Liabilities | $6,361,627 | $6,343,435 | +0.3% | | Total Stockholders' Equity | $8,388,050 | $3,098,585 | +170.7%| [Consolidated Statements of Operations](index=7&type=section&id=CONSOLIDATED%20STATEMENTS%20OF%20OPERATIONS%20AND%20COMPREHENSIVE%20LOSS) For the year ended December 31, 2023, revenues decreased significantly by 84% to $152,430. However, total operating expenses were nearly halved, leading to a substantial reduction in net loss by 31% to $(10,910,288). Basic and diluted net loss per share improved from $(5.19) in 2022 to $(2.43) in 2023 Consolidated Statements of Operations Highlights | Metric | 2023 | 2022 | Change (%) | | :-------------------------------- | :------------- | :------------- | :--------- | | Revenues | $152,430 | $969,783 | -84.3% | | Gross (loss) profit | $(149,607) | $683,368 | -121.9% | | Total operating expenses | $8,066,902 | $15,797,780 | -48.9% | | Loss from operations | $(8,216,509) | $(15,114,412) | -45.6% | | Total other income (expenses) | $(2,437,773) | $(400,184) | +509.1% | | Net loss | $(10,910,288) | $(16,312,374) | -33.1% | | Net loss per share (Basic & Diluted) | $(2.43) | $(5.19) | -53.1% | [Consolidated Statements of Cash Flows](index=8&type=section&id=CONSOLIDATED%20STATEMENTS%20OF%20CASH%20FLOWS) Net cash used in operating activities decreased by 42.7% to $(4,235,845) in 2023. Cash flows from financing activities provided $3,918,960, primarily from the issuance of common stock, warrants, and convertible notes, partially offsetting the cash used in operations and investing Consolidated Statements of Cash Flows Highlights | Metric | 2023 | 2022 | Change (%) | | :--------------------------------------- | :------------- | :------------- | :--------- | | Net cash used in operating activities | $(4,235,845) | $(7,398,391) | -42.7% | | Net cash used in investing activities | $(360,186) | $(1,721,684) | -79.1% | | Net cash provided by financing activities | $3,918,960 | $4,013,925 | -2.4% | | Net increase (decrease) in cash and cash equivalents and restricted cash | $(674,948) | $(5,173,487) | -86.9% | | Cash and cash equivalents and restricted cash (Ending) | $716,780 | $1,391,728 | -48.5% | - Significant non-cash financing activity included the purchase of property and equipment by issuing common stock to a third party for **$7,400,000**[32](index=32&type=chunk) - Issuance of common stock for conversion of debt amounted to **$3,306,112**[32](index=32&type=chunk) [Legal Disclaimers & Contact Information](index=5&type=section&id=Forward-Looking%20Statements) This section provides standard forward-looking statements disclaimers and contact information for investor inquiries [Legal Disclaimers & Contact Information Overview](index=5&type=section&id=Legal%20Disclaimers%20%26%20Contact%20Information_Overview) This section includes standard forward-looking statements disclaimers, emphasizing that clinical trials are in early stages and future performance is subject to various risks and uncertainties. It also clarifies that the press release does not constitute an offer to sell securities and provides contact information for investor inquiries - Clinical trials are in early stages, and there is no guarantee that any specific outcome will be achieved[27](index=27&type=chunk) - Forward-looking statements are subject to known and unknown risks and uncertainties, many beyond the Company's control, which may cause actual results to differ materially[27](index=27&type=chunk) - The press release does not constitute an offer to sell or the solicitation of an offer to buy securities[28](index=28&type=chunk) - Contact information for investor inquiries is provided: Leeds Chow, Email: **leedschow@ambrivis.com**[28](index=28&type=chunk)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-40700 ABVC BioPharma, Inc. (Exact name of Company in its charter) Nevada 26-0014658 (State or other jurisdiction of (I.R.S. Employer incorporation o ...

FREMONT, CA, Feb. 27, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ:ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and oncology/hematology, today provided an update on its development of combination therapy for the treatment of cancer and immunity booster dietary supplements. The Company is currently marketing dietary supplements, as well as continuing to pursue clinical trials of phar ...

Registration No. 333-276500 Registration No. 333-271416 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 2 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ABVC BIOPHARMA, INC. (Exact name of registrant as specified in its charter) As filed with the Securities and Exchange Commission on February 16, 2024 (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) Nevada 5084 26-0014658 (I.R.S. Employer Iden ...